Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Type
Public
HQ
Milton, GB
Founded
2003
Size (employees)
44 (est)
Summit Therapeutics was founded in 2003 and is headquartered in Milton, GB
Report incorrect company information

Summit Therapeutics Office Locations

Summit Therapeutics has offices in Milton and Cambridge
Milton, GB (HQ)
Park House Park Dr 85b
Cambridge, US
1 Broadway
Show all (2)
Report incorrect company information

Summit Therapeutics Financials and Metrics

Summit Therapeutics Revenue

Summit Therapeutics's revenue was reported to be £2.30 m in FY, 2017
GBP

Revenue (FY, 2017)

2.3 m

Net income (FY, 2017)

(21.4 m)

EBITDA (FY, 2017)

(24.8 m)

EBIT (FY, 2017)

(24.9 m)

Cash (31-Jan-2017)

28.1 m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

113 k531 k1 m3 m1.8 m189 k763 k1.8 m1.8 m1.8 m2.1 m1.5 m2.3 m

Revenue growth, %

16%(32%)

Cost of goods sold

279 k233 k304 k1.6 m1.1 m

Gross profit

(166 k)298 k730 k1.4 m773 k
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

14.2 m12.6 m18.3 m10.1 m2.7 m6.1 m3.3 m2.1 m3.4 m2 m11.3 m16.3 m28.1 m

Accounts Receivable

40 k129 k283 k189 k651 k41 k32 k47 k51 k

Inventories

27 k187 k337 k391 k

Current Assets

14.3 m13.2 m19.6 m12.7 m5.4 m6.6 m3.7 m2.6 m4.2 m3.1 m15.2 m20.8 m33.3 m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(499 k)(995 k)(3 m)(10.1 m)(22.4 m)(6.2 m)(4.7 m)(2.7 m)(4.2 m)(6.1 m)(11.4 m)(20.1 m)(21.4 m)

Cash From Operating Activities

185 k1.4 m3.2 m8.1 m(10.1 m)(3.1 m)(2.7 m)(2.4 m)(3.2 m)(5.9 m)(11.3 m)(17.2 m)12.1 m

Cash From Financing Activities

14.1 m757 k9.9 m633 k3.6 m5 m14 k1.4 m4.6 m4.5 m20.5 m22.1 m413 k

Net Change in Cash

282 k678 k2.2 m8.2 m(7.4 m)3.4 m(2.8 m)(1.2 m)1.3 m(1.3 m)9.2 m4.9 m12.5 m
GBPY, 2017

Revenue/Employee

56.9 k

Financial Leverage

-10.8 x
Show all financial metrics
Report incorrect company information

Summit Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Summit Therapeutics News and Updates

Summit Therapeutics to stop developing muscle-wasting disorder drug

June 27 (Reuters) - Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed to meet the goals of a mid-stage study.
Report incorrect company information

Summit Therapeutics Company Life and Culture

Report incorrect company information